Markers of MEK inhibitor resistance in low-grade serous ovarian cancer: EGFR is a potential therapeutic target

BACKGROUND: Although low-grade serous ovarian cancer (LGSC) is rare, case-fatality rates are high as most patients present with advanced disease and current cytotoxic therapies are not overly effective. Recognizing that these cancers may be driven by MAPK pathway activation, MEK inhibitors (MEKi) ar...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Cancer Cell Int
Glavni autori: Fernandez, Marta Llaurado, Dawson, Amy, Hoenisch, Joshua, Kim, Hannah, Bamford, Sylvia, Salamanca, Clara, DiMattia, Gabriel, Shepherd, Trevor, Cremona, Mattia, Hennessy, Bryan, Anderson, Shawn, Volik, Stanislav, Collins, Colin C., Huntsman, David G., Carey, Mark S.
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2019
Teme:
Primary Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6325847/
https://ncbi.nlm.nih.gov/pubmed/30636931
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12935-019-0725-1
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items